Literature DB >> 12352891

C4d staining of perioperative renal transplant biopsies.

Mark Haas1, Lloyd E Ratner, Robert A Montgomery.   

Abstract

BACKGROUND: Deposition of C4d in peritubular capillaries (PTCs) has been shown to be a sensitive marker for antibody-mediated (humoral) rejection in renal transplant biopsies. Some studies also suggest that C4d in PTCs is specific for humoral rejection or, at least, for the presence of donor-specific antibodies. However, in other studies, PTC C4d deposits were noted in more than 40% of renal transplant biopsies performed for graft dysfunction and capillary C4d deposition in heart transplants may result from ischemic injury.
METHODS: To test the specificity of C4d staining as a marker for acute humoral rejection ACR in renal allografts, indirect immunofluorescence using a monoclonal anti-C4d antibody and a fluorescein-isothiocyanate-conjugated secondary antibody was performed on cryostat sections of 90 renal transplant biopsies, including 35 pairs of preimplantation and 1-hr postreperfusion biopsies of the same graft, postreperfusion biopsies of 12 additional grafts, and 8 positive controls (biopsies with known C4d-positive AHR). Eighteen grafts were cadaveric, 17 grafts were liviing-related, and 12 grafts were living-unrelated (excluding controls). Included in these grafts were 13 grafts that developed AHR 3 to 34 days posttransplantation.
RESULTS: Only 2 of 82 perioperative biopsies showed C4d staining in PTCs. Both perioperative biopsies were postreperfusion biopsies of grafts diagnosed with AHR 5 and 34 days posttransplantation, respectively, and, in each case, the recipient had been treated with plasmapheresis before transplantation because of a positive crossmatch (cytotoxic and flow cytometric) and continued to have a weakly positive flow crossmatch at the time of transplantation. In one biopsy, C4d staining was focal, and in the other biopsy, it was diffuse; in both biopsies, C4d staining was relatively mild (1+ on a 0-4+ scale). No C4d staining was noted on preimplantation biopsies of each graft. All biopsies that contained glomeruli showed linear capillary loop or blotchy mesangial staining, or both, which was similar in prereperfusion and postreperfusion biopsies. All positive controls showed diffuse C4d staining in PTCs.
CONCLUSIONS: C4d staining in PTCs may be seen as early as 1 hr posttransplantation in some recipients with low levels of antidonor antibodies. However, this was not observed as a feature of ischemic or ischemia-reperfusion injury in perioperative renal transplant biopsies, including those of cadaveric grafts with cold ischemia times of as long as 41 hr.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12352891     DOI: 10.1097/00007890-200209150-00021

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

Review 1.  [Alloantibodies-mediated kidney transplant rejection: a pair of continuing approaches, and with nonetheless many open questions].

Authors:  Georg Böhmig
Journal:  Wien Klin Wochenschr       Date:  2006-07       Impact factor: 1.704

2.  Pathology: donor biopsy evaluation at time of renal grafting.

Authors:  Volker Nickeleit
Journal:  Nat Rev Nephrol       Date:  2009-05       Impact factor: 28.314

Review 3.  Pros and cons for C4d as a biomarker.

Authors:  Danielle Cohen; Robert B Colvin; Mohamed R Daha; Cinthia B Drachenberg; Mark Haas; Volker Nickeleit; Jane E Salmon; Banu Sis; Ming-Hui Zhao; Jan A Bruijn; Ingeborg M Bajema
Journal:  Kidney Int       Date:  2012-02-01       Impact factor: 10.612

4.  Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage.

Authors:  Giuseppe Castellano; Rita Melchiorre; Antonia Loverre; Pasquale Ditonno; Vincenzo Montinaro; Michele Rossini; Chiara Divella; Michele Battaglia; Giuseppe Lucarelli; Gennaro Annunziata; Silvano Palazzo; Francesco Paolo Selvaggi; Francesco Staffieri; Antonio Crovace; Mohamed R Daha; Maurice Mannesse; Sandra van Wetering; Francesco Paolo Schena; Giuseppe Grandaliano
Journal:  Am J Pathol       Date:  2010-02-11       Impact factor: 4.307

5.  Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation.

Authors:  Candice Roufosse; Jan Ulrich Becker; Marion Rabant; Daniel Seron; Maria Irene Bellini; Georg A Böhmig; Klemens Budde; Fritz Diekmann; Denis Glotz; Luuk Hilbrands; Alexandre Loupy; Rainer Oberbauer; Liset Pengel; Stefan Schneeberger; Maarten Naesens
Journal:  Transpl Int       Date:  2022-05-20       Impact factor: 3.842

6.  Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys.

Authors:  R N Smith; T Kawai; S Boskovic; O Nadazdin; D H Sachs; A B Cosimi; R B Colvin
Journal:  Am J Transplant       Date:  2008-06-28       Impact factor: 8.086

7.  Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients.

Authors:  Arjang Djamali; Brenda L Muth; Thomas M Ellis; Maha Mohamed; Luis A Fernandez; Karen M Miller; Janet M Bellingham; Jon S Odorico; Joshua D Mezrich; John D Pirsch; Tony M D'Alessandro; Vijay Vidyasagar; R Michael Hofmann; Jose R Torrealba; Dixon B Kaufman; David P Foley
Journal:  Kidney Int       Date:  2013-02-27       Impact factor: 10.612

8.  The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.

Authors:  M Haas; A Loupy; C Lefaucheur; C Roufosse; D Glotz; D Seron; B J Nankivell; P F Halloran; R B Colvin; Enver Akalin; N Alachkar; S Bagnasco; Y Bouatou; J U Becker; L D Cornell; J P Duong van Huyen; I W Gibson; Edward S Kraus; R B Mannon; M Naesens; V Nickeleit; P Nickerson; D L Segev; H K Singh; M Stegall; P Randhawa; L Racusen; K Solez; M Mengel
Journal:  Am J Transplant       Date:  2018-01-21       Impact factor: 8.086

9.  Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection.

Authors:  Katherine M Dominy; Michelle Willicombe; Tariq Al Johani; Hannah Beckwith; Dawn Goodall; Paul Brookes; H Terence Cook; Tom Cairns; Adam McLean; Candice Roufosse
Journal:  Kidney Int Rep       Date:  2018-09-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.